Clinical Trials on Acute Chest Syndrome

Total 45934 results

Randy Windreich

Completed

Reduced-Intensity Conditioning (RIC) and Myeloablative Conditioning (MAC) for HSCT in AML/MDS

Acute Myeloid Leukemia (AML) | Myelodysplastic Syndrome (MDS) | Hematopoietic Stem Cell Transplant (HSCT)

United States
University of Sao Paulo General Hospital

Unknown

Registry Of Acute meDical Emergencies in Brazil (ROAD-Brazil)

Heart Failure | Chest Pain | Syncope | Pulmonary Embolism | Pulmonary Edema | Acute Coronary Syndromes | Aortic Aneurysm, Familial Thoracic 1

Brazil
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Suspended

211At-BC8-B10 Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory High-Risk Acute Leukemia or Myelodysplastic Syndrome

Hematopoietic and Lymphoid Cell Neoplasm | Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome | Chronic Myelomonocytic Leukemia | Recurrent Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Myelodysplastic Syndrome With Excess Blasts | Recurrent Acute Lymphoblastic... and other conditions

United States
University Hospital, Basel, Switzerland

Recruiting

Emergency Department Triage of Patients With Acute Chest Pain Based on the ESC 0/1-hour Algorithm (PRESC1SE-MI) (PRESC1SE-MI)

NSTEMI - Non-ST Segment Elevation MI | Acute Chest Pain

United Kingdom, Switzerland, Spain, Korea, Republic of, United States, Australia, Austria, Finland, Greece, Italy, Romania
National Cancer Institute (NCI)

Completed

Combination Chemotherapy With or Without Bone Marrow Transplantation in Treating Children With Acute Myelogenous Leukemia or Myelodysplastic Syndrome

Chronic Myelomonocytic Leukemia | Childhood Acute Erythroleukemia (M6) | Childhood Acute Megakaryocytic Leukemia (M7) | Childhood Acute Monoblastic Leukemia (M5a) | Childhood Acute Monocytic Leukemia (M5b) | Childhood Acute Myeloblastic Leukemia With Maturation (M2) | Childhood Acute Myeloblastic... and other conditions

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Recruiting

Graft Versus Host Disease-Reduction Strategies for Donor Blood Stem Cell Transplant Patients With Acute Leukemia or Myelodysplastic Syndrome (MDS)

Acute Myeloid Leukemia | Acute Lymphoblastic Leukemia | Acute Leukemia | Myelodysplastic Syndrome

United States
National Cancer Institute (NCI)

Completed

Busulfan, Fludarabine Phosphate, and Anti-Thymocyte Globulin Followed By Donor Stem Cell Transplant and Azacitidine in Treating Patients With High-Risk Myelodysplastic Syndrome and Older Patients With Acute Myeloid Leukemia

Acute Myeloid Leukemia | Recurrent Adult Acute Myeloid Leukemia | Myelodysplastic Syndrome | Myelodysplastic Syndrome With Excess Blasts | Secondary Myelodysplastic Syndrome | de Novo Myelodysplastic Syndrome | Adult Acute Monoblastic Leukemia | Adult Acute Monocytic Leukemia | Adult Acute Myeloid Leukemia... and other conditions

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Recruiting

Fludarabine Phosphate, Cytarabine, Filgrastim-sndz, Gemtuzumab Ozogamicin, and Idarubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

Untreated Adult Acute Myeloid Leukemia | Myelodysplastic Syndrome With Excess Blasts | High Risk Myelodysplastic Syndrome | de Novo Myelodysplastic Syndrome | Acute Myeloid Leukemia With t(8;21); (q22; q22.1); RUNX1-RUNX1T1 | Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11 | Acute Myeloid... and other conditions

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Nivolumab and Azacitidine With or Without Ipilimumab in Treating Patients With Refractory/Relapsed or Newly Diagnosed Acute Myeloid Leukemia

Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome | Chronic Myelomonocytic Leukemia | Secondary Acute Myeloid Leukemia | Myelodysplastic Syndrome | Recurrent Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Therapy-Related Acute Myeloid Leukemia | Acute Bilineal Leukemia and other conditions

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Cognitive Behavioral Therapy in Helping Patients With Acute Myeloid Leukemia or Lymphoma With Cancer-Related Fatigue

Lymphoma | Acute Myeloid Leukemia | Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome | Secondary Acute Myeloid Leukemia | Cancer Fatigue

United States
Bristol-Myers Squibb

Not yet recruiting

Study of BMS-986497 (ORM-6151) in Participants With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome

Acute Myeloid Leukemia | Myelodysplastic Syndrome

United States, Canada
Chordia Therapeutics, Inc.
Theradex

Recruiting

A Study of CTX-712 in Relapsed/Refractory Acute Myeloid Leukemia and Higher Risk Myelodysplastic Syndromes

Acute Myeloid Leukemia | Myelodysplastic Syndromes

United States
Fred Hutchinson Cancer Center
Medexus Pharma, Inc.

Recruiting

Treosulfan-Based Versus Clofarabine-Based Conditioning Before Donor Hematopoietic Stem Cell Transplant for the Treatment of Myelodysplastic Syndromes or Acute Myeloid Leukemia

Acute Myeloid Leukemia | Myelodysplastic Syndrome

United States
Celgene

Recruiting

Study to Evaluate Safety and Tolerability of CC-91633 (BMS-986397) in Participants With Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractory Higher-Risk Myelodysplastic Syndromes

Myelodysplastic Syndromes | Leukemia, Myeloid, Acute

United States, Australia, Spain, Canada, United Kingdom
Novartis Pharmaceuticals

Withdrawn

A Study of Sabatolimab and Magrolimab-based Treatment in AML or Higher Risk MDS Participants

Acute Myeloid Leukemia | Myelodysplastic Syndromes
Syros Pharmaceuticals

Completed

A Biomarker-Directed Phase 2 Trial of Tamibarotene (SY-1425) in Participants With Acute Myeloid Leukemia or Myelodysplastic Syndrome

Acute Myeloid Leukemia | Myelodysplastic Syndrome

United States, France
Masonic Cancer Center, University of Minnesota

Completed

Nivolumab and Oral Cyclophosphamide for R/R AML and HIgh Risk MDS

Acute Myeloid Leukemia | Higher Risk Myelodysplastic Syndrome

United States
University of California, Davis
Celgene

Completed

Study of Lenalidomide in Patients With Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome

Acute Myeloid Leukemia | Myelodysplastic Syndrome

United States
University of Miami
Gabrielle's Angel Foundation; Women's Cancer Association

Completed

Study of TCP-ATRA for Adult Patients With AML and MDS (TCP-ATRA)

Myelodysplastic Syndromes | Leukemia | Acute Myelogenous Leukemia

United States
M.D. Anderson Cancer Center
Eisai Inc.

Completed

Decitabine (DAC) w/ or w/o Valproic Acid (VPA) in Myelodysplastic Syndrome (MDS) and Acute Myelogenous Leukemia (AML)

Myelodysplastic Syndrome | Acute Myelogenous Leukemia

United States
BioMed Valley Discoveries, Inc

Completed

Phase 1/2 Study of the ERK1/2 Inhibitor BVD-523 in Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndromes

Myelodysplastic Syndrome | Acute Myelogenous Leukemia

United States
Celgene

Terminated

A Study of CC-90002 in Subjects With Acute Myeloid Leukemia (AML) and High-risk Myelodysplastic Syndrome (MDS)

Myelodysplastic Syndromes | Leukemia, Myeloid, Acute

United States
Hospices Civils de Lyon

Unknown

Study of the Outcome of Patients With Acute Myeloblastic Leukemia and Myelodysplastic Syndrome Receiving Iron Chelation Therapy After Allogeneic Hematopoietic Stem Cell Transplantation (GREFFE)

Myelodysplastic Syndromes | Myeloid Leukemia

France
Johann Wolfgang Goethe University Hospital

Unknown

Phase I/II Study With Oral Panobinostat Maintenance Therapy Following Allogeneic Stem Cell Transplantation in Patients With High Risk Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML) (PANOBEST)

Acute Myeloid Leukemia | Myelodysplastic Syndrome

Germany
Novartis Pharmaceuticals

Completed

PKC412 in Participants With Acute Myeloid Leukemia or With Myelodysplastic Syndrome (CPKC412A2104 Core); and PKC412 in Participants With Acute Myeloid Leukemia or With Myelodysplastic Syndrome With Either Wild Type or Mutated FMS-like Tyrosine Kinase 3 (FLT3) (CPKC412A2104E1 and CPKC412A2104E2)

Acute Myeloid Leukemia | Myelodysplastic Syndromes

United States
Onconova Therapeutics, Inc.

Completed

Study of 72-Hour Infusion of ON 01910.Na in Patients With MDS or AML

Acute Myeloid Leukemia | Myelodysplastic Syndrome

United States
Dr. Avichai Shimoni MD

Completed

Treosulfan-based Conditioning for Transplantation in AML/MDS

Acute Myeloid Leukemia | Myelodysplastic Syndrome

Israel
BioMAS Ltd

Suspended

Safety and Efficacy Study of AS101 to Treat Elderly Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) Patients

Acute Myeloid Leukemia | Myelodysplastic Syndrome

Israel
Medical Research Council

Completed

Combination Chemotherapy With or Without Bone Marrow Transplantation in Treating Children With Acute Myeloid Leukemia

Myelodysplastic Syndromes | Leukemia

United Kingdom
Weill Medical College of Cornell University

Completed

Mylotarg and Ara-C in Untreated Patients Above 60 Years With AML and High-Risk MDS

Acute Myeloid Leukemia | Myelodysplastic Syndrome

United States
Eisai Inc.

Completed

Trial of Decitabine in Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndrome

Myelodysplastic Syndrome | Acute Myelogenous Leukemia

United States
Dana-Farber Cancer Institute
Brigham and Women's Hospital

Completed

A Study of All-Trans Retinoic Acid (ATRA) and Bryostatin in Patients With Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)

Myelodysplastic Syndrome | Acute Myelogenous Leukemia

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Completed

Gemtuzumab Ozogamicin, Fludarabine, and Total-body Irradiation Followed by Peripheral Stem Cell or Bone Marrow Transplantation in Treating Patients With Advanced Acute Myeloid Leukemia or Myelodysplastic Syndrome

Myelodysplastic Syndromes | Leukemia

United States
Shenyang Northern Hospital

Completed

Effects of Optimized Antiplatelet Treatment After Percutaneous Coronary Intervention

Ischemic Heart Disease | Acute Coronary Syndromes

China
Samsung Medical Center
Jin Yang Pharmaceutical

Suspended

L-Ascorbic Acid Depletion to Treat Acute Myeloid Leukemia and Myelodysplastic Syndromes

Acute Myeloid Leukemia | Myelodysplastic Syndrome

Korea, Republic of
Children's Oncology Group

Not yet recruiting

A Study to Find the Highest Dose of Imetelstat in Combination With Fludarabine and Cytarabine for Patients With AML, MDS or JMML That Has Come Back or Does Not Respond to Therapy

Recurrent Acute Myeloid Leukemia | Recurrent Myelodysplastic Syndrome | Refractory Acute Myeloid Leukemia | Refractory Myelodysplastic Syndrome | Recurrent Juvenile Myelomonocytic Leukemia | Refractory Juvenile Myelomonocytic Leukemia
Maastricht University
Maastricht University Medical Center; Zuyderland Medisch Centrum

Not yet recruiting

Could Ki-67 be Used as a Diagnostic or Prognostic Marker in Hemato-oncological Diagnostics?

Acute Myeloid Leukemia | Myelodysplastic Syndromes | Myelodysplastic Syndrome/Neoplasm
National Cancer Institute (NCI)

Completed

Combination Chemotherapy and Dasatinib in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia

Acute Myeloid Leukemia | Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome | Secondary Acute Myeloid Leukemia | Therapy-Related Acute Myeloid Leukemia | Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11 | Adult Acute Myeloid Leukemia With t(16;16)(p13.1;q22)... and other conditions

United States
Sanofi
Bristol-Myers Squibb

Completed

Clopidogrel as Adjunctive Reperfusion Therapy - Thrombolysis in Myocardial Infarction (CLARITY-TIMI28)

Acute Coronary Syndromes

Russian Federation, Belgium, Brazil, France, Germany, Hungary, Italy, Mexico, Netherlands, South Africa, Spain, Sweden, United States, Argentina, Australia, Ireland, Israel, Turkey, Austria, Poland, Canada, Portugal, Puerto Rico, United...
Hospices Civils de Lyon

Not yet recruiting

Role of BMP Pathway in MDS Progression (BMP-MDS)

Myelodysplastic Syndromes | Acute Myelogenous Leukemia

France
GluBio Therapeutics Inc.

Recruiting

A Study of GLB-001 in Patients With Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractory Higher Risk Myelodysplastic Syndromes

Acute Myeloid Leukemia | Myelodysplastic Syndromes

United States
GeneScience Pharmaceuticals Co., Ltd.
Ruijin Hospital; Shanghai Tong Ren Hospital; First Affiliated Hospital of Zhejiang...

Recruiting

Gentulizumab in Relapsed/Refractory Acute Myelogenous Leukemia or Myelodysplastic Syndrome

Myelodysplastic Syndromes | Acute Myelogenous Leukemia

China
Curis, Inc.

Recruiting

Dose Escalation/ Expansion Study of CA-4948 as Monotherapy in Patients With AML or MDS

Myelodysplastic Syndrome | Acute Myelogenous Leukemia

Germany, United States, Spain, Israel, Czechia, Poland, France, Italy
Edgewood Oncology Inc.

Recruiting

A Study of BTX-A51 in People With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

Acute Myeloid Leukemia | Myelodysplastic Syndrome

United States
Celyad Oncology SA

Recruiting

Study in Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Patients to Determine the Recommended Dose of CYAD-02 (CYCLE-1)

Acute Myeloid Leukemia | Myelodysplastic Syndrome

Belgium, United States
Institut Paoli-Calmettes

Recruiting

COaching and Prehabilitation: Faisability Study in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndrome (COHABILIT)

Acute Myeloid Leukemia | Myelodysplastic Syndromes

France
Celgene

Terminated

A Dose-finding Study of CC-90009 in Subjects With Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractory Higher-risk Myelodysplastic Syndromes

Myelodysplastic Syndromes | Leukemia, Myeloid, Acute

United States, France, Canada, Norway, Spain, United Kingdom
Bristol-Myers Squibb

Active, not recruiting

A Study to Assess the Effect of CC-95251 in Participants With Acute Myeloid Leukemia and Myelodysplastic Syndromes

Myelodysplastic Syndromes | Leukemia, Myeloid, Acute

United States, France, Australia, Canada, Italy, Norway, Spain, Sweden, United Kingdom
Celgene

Completed

A Study to Analyze the Occurrence of Transformation From Myelodysplastic Syndrome to Acute Myeloid Leukemia in Patients With Myelodysplastic Syndrome Who Received Revlimid® 5 mg Capsules and Who Are Continuing or no Longer Continuing Revlimid Treatment

Myelodysplastic Syndromes | Leukemia, Myeloid, Acute

Japan
Technische Universität Dresden

Completed

Treatment of Patients With Myelodysplastic Syndrome or Acute Myelocytic Leukemia With an Impending Hematological Relapse With Azacitidine (Vidaza) (RELAZA2)

Myelodysplastic Syndrome | Acute Myelocytic Leukemia

Germany

Clinical Trials on Acute Chest Syndrome

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Thailand

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations